Hematopathologic findings in chronic idiopathic myelofibrosis

被引:48
作者
Thiele, J [1 ]
Kvasnicka, HM [1 ]
机构
[1] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
关键词
D O I
10.1053/j.seminoncol.2005.04.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Until now scant knowledge was available about the dynamics of chronic idiopathic myelofibrosis (CIMF). However, follow-up studies are in keeping with a stepwise evolution starting with a prefibrotic (hypercellular) phase that progressively transforms into the classical fibro-osteosclerotic endstage with myeloid metaplasia. Prefibrotic CIMF is characterized by a granulocytic and megakaryocytic myeloproliferation lacking an increase in reticulin. Most conspicuous are abnormalities of megakaryopoiesis with regard to their histotopography and maturation. There is a more than 65% probability of progression from an early to advanced CIMF accompanied by increasing anemia, splenomegaly, and leuko-erythroblastosis. A significant relationship is recognizable among frequency, tortuosity, and luminal dilation of the microvessels and the extent of myelofibrosis. Quantity of CD34+ progenitor cells in the bone marrow (BM) reveals a close association with advancement of disease (fibrosis, splenomegaly, anemia, peripheral blasts) and therefore prognosis. Cell kinetic studies show increased proliferation associated with a higher rate of apoptosis in initial (hypercellular) stages, as well as a reduced endoreduplicative activity of megakaryopoiesis and a blocked synthesis phase of the erythroid precursors. It is noteworthy that prefibrotic and early CIMF often present with a marked thrombocytosis mimicking essential thrombocythemia. Regarding prognosis, early CIMF is associated with a significantly more favorable survival than advanced stages. © 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:380 / 394
页数:15
相关论文
共 139 条
[91]   Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases [J].
Reilly, JT ;
Snowden, JA ;
Spearing, RL ;
Fitzgerald, PM ;
Jones, N ;
Watmore, A ;
Potter, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (01) :96-102
[92]   ENDOTHELIAL-CELL PROLIFERATION IN MYELOFIBROSIS [J].
REILLY, JT ;
NASH, JRG ;
MACKIE, MJ ;
MCVERRY, BA .
BRITISH JOURNAL OF HAEMATOLOGY, 1985, 60 (04) :625-630
[93]   Idiopathic myelofibrosis: pathogenesis, natural history and management [J].
Reilly, JT .
BLOOD REVIEWS, 1997, 11 (04) :233-242
[94]  
ROZMAN C, 1991, CANCER, V67, P2658, DOI 10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO
[95]  
2-C
[96]   PRIMARY MYELOFIBROSIS - A DETAILED STATISTICAL-ANALYSIS OF THE CLINICOPATHOLOGICAL VARIABLES INFLUENCING SURVIVAL [J].
RUPOLI, S ;
DALIO, L ;
SISTI, S ;
CAMPANATI, G ;
SALVI, A ;
BRIANZONI, MF ;
DAMICO, S ;
CINCIRIPINI, A ;
LEONI, P .
ANNALS OF HEMATOLOGY, 1994, 68 (04) :205-212
[97]   THE ROLE OF ALPHA-INTERFERON IN ESSENTIAL THROMBOCYTHEMIA, POLYCYTHEMIA-VERA AND MYELOFIBROSIS WITH MYELOID METAPLASIA (MMM) - A CONCISE UPDATE [J].
SACCHI, S .
LEUKEMIA & LYMPHOMA, 1995, 19 (1-2) :13-20
[98]   Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells -: In vivo neovascularization induced by stromal-derived factor-1α [J].
Salcedo, R ;
Wasserman, K ;
Young, HA ;
Grimm, MC ;
Howard, OMZ ;
Anver, MR ;
Kleinman, HK ;
Murphy, WJ ;
Oppenheim, JJ .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (04) :1125-1135
[99]   Medical progress: Myelofibrosis with myeloid metaplasia. [J].
Tefferi, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (17) :1255-1265
[100]   Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia [J].
Tefferi, A ;
Mesa, RA ;
Gray, LA ;
Steensma, DP ;
Camoriano, JK ;
Elliott, MA ;
Pardanani, A ;
Ansell, SM ;
Call, TG ;
Colon-Otero, G ;
Schroeder, G ;
Hanson, CA ;
Dewald, GW ;
Kaufmann, SH .
BLOOD, 2002, 99 (10) :3854-3856